You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 41 No. 11, November 1984 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Schneider's First-Rank Symptoms of Schizophrenia

An Association With Increased Growth Hormone Response to Apomorphine

Lawrence J. Whalley, MD, MRCPsych; Janice E. Christie, MB, MRCPsych; Sandy Brown, PhD; Gordon W. Arbuthnott, PhD

Arch Gen Psychiatry. 1984;41(11):1040-1043.


Abstract

• Growth hormone and prolactin (PRL) responses to 0.75 mg of apomorphine hydrochloride were measured in 19 newly admitted psychotic patients who had been untreated by neuroleptic or antidepressant drugs for at least nine months. We compared hormonal responses between subgroups of patients who were distinguished using the diagnostic criteria of Feighner et al and Spitzer et al, and by the presence or absence of Schneider's first-rank symptoms of schizophrenia. We included nine healthy subjects who were matched by age and sex with the schizophrenic patients. Growth hormone responses to apomorphine were greater in patients with Schneider's first-rank symptoms than in those without firstrank symptoms, and were also greater than in control subjects. Suppression of plasma PRL was also greater in schizophrenic patients than in control subjects. These results support the dopamine hypothesis of schizophrenia.



Author Affiliations

From the Medical Research Council Brain Metabolism Unit, Royal Edinburgh Hospital, and the Department of Pharmacology, University of Edinburgh (Drs Whalley, Christie, and Arbuthnott); and the Immunoassay Section, Department of Clinical Chemistry, University of Edinburgh (Dr Brown). Dr Brown is now with the Department of Clinical Biochemistry, Central Pathology Laboratory, Stoke-on-Trent, England.


Footnotes

Accepted for publication March 1, 1984.

Reprint requests to MRC Brain Metabolism Unit, University Department of Pharmacology, 1 George Square, Edinburgh, Scotland (Dr Whalley).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Brain Morphology, Dopamine, and Eye-Tracking Abnormalities in First-Episode Schizophrenia: Prevalence and Clinical Correlates
Lieberman et al.
Arch Gen Psychiatry 1993;50:357-368.
ABSTRACT  

Growth Hormone Response to Apomorphine
Ferrier et al.
Arch Gen Psychiatry 1987;44:93-93.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1984 American Medical Association. All Rights Reserved.